DOSSIER · 13F-HR · Q1 2026

Vestal Point Capital, LP

$3.6B in tracked AUM across 90 positions as of Q1 2026.

VP
CIK 0001974915 · last filed Mar 31, 2026
Total AUM
$3.6B
as of Q1 2026
Holdings
90
positions
Whale Score
63
63
tracked
Activity
no data
changes this Q
AI Analysis · Q1 2026
Vestal Point Capital, LP (SEC 13F) Analysis

Report Period: Q3 2025 (Report Date: September 30, 2025)

1. Portfolio Overview

Vestal Point Capital manages a concentrated portfolio totaling approximately $1.37 billion across 52 holdings. The firm experienced a significant reduction in assets under management (AUM) during the quarter, with the portfolio value declining by 27.7% from $1.90 billion in the previous quarter (Q2 2025). This decline suggests a combination of realized los...

The portfolio exhibits a high-conviction strategy characterized by moderate concentration. The top ten positions account for roughly 50% of the total portfolio value, with individual position sizes ranging from approximately 8.7% down to 0.1%. The turnover for the quarter was exceptionally high, with 25 new positions initiated and 25 positions sold completely, indicating a dynamic and actively managed approach to biotech investing.

2. Key Holdings
Analysis generated by 13F Insight from SEC Form 13F filing data · Q1 2026. Methodology

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
RVMD
Revolution Medicines Inc
$231M2.4M6.5%
02
BMRN
BioMarin Pharmaceutical Inc
$202M3.6M5.6%
03
ABVX
Abivax SA
$167M1.5M4.7%
04
NBIX
Neurocrine Biosciences Inc
$165M1.3M4.6%
05
ARWR
Arrowhead Pharmaceuticals Inc
$143M2.3M4.0%
06
ELVN
Enliven Therapeutics Inc
$127M3.3M3.6%
07
RGEN
Repligen Corp
$109M925K3.0%
08
BCAX
Bicara Therapeutics Inc
$108M5.4M3.0%
09
NRIX
Nurix Therapeutics Inc
$101M6.5M2.8%
10
APGE
Apogee Therapeutics Inc
$93M1.1M2.6%

Filing history

2026Q1Mar 31
$3.6B 21.6%
90 positionsView →
2025Q4Dec 31
$2.9B 114.1%
76 positionsView →
2025Q3Sep 30
$1.4B 27.7%
52 positionsView →
2025Q2Jun 30
$1.9B 35.6%
72 positionsLocked
2025Q1Mar 31
$1.4B 17.0%
63 positionsLocked
2024Q4Dec 31
$1.7B 27.9%
73 positionsLocked
2024Q3Sep 30
$1.3B 1.7%
69 positionsLocked
2024Q2Jun 30
$1.3B 10.9%
60 positionsLocked
2024Q1Mar 31
$1.2B 28.1%
58 positionsLocked
2023Q4Dec 31
$944M
48 positionsLocked